<DOC>
	<DOCNO>NCT01289041</DOCNO>
	<brief_summary>This prospective multi-center , open-label , single arm , Phase II study investigate safety efficacy BKM120 patient advance endometrial carcinoma whose disease progress first-line antineoplastic treatment . Patients receive BKM120 orally dose 100 mg/day . Availability tumor specimen ( either archival tissue fix fresh biopsy ) mandatory assessment PI3K ( Phosphatidylinositol 3 Kinase ( PI3K ) pathway activation status .</brief_summary>
	<brief_title>BKM120 Second-line Therapy Advanced Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 2 histologically confirm diagnosis advance endometrial carcinoma available tissue specimen identification PI3K pathway activation ( archival tissue fix fresh biopsy ) one prior line antineoplastic treatment cytotoxic agent objective progression disease prior treatment least one measurable lesion per RECIST criterion adequate bone marrow organ function previous treatment PI3K and/or mTOR inhibitor symptomatic CNS metastasis concurrent malignancy malignancy within 3 year study enrollment Active mood disorder judge investigator medically document history mood disorder ( e.g . major depressive episode , bipolar disorder , obsessivecompulsive disorder , schizophrenia , etc . ) , ≥ CTCAE grade 3 anxiety pelvic and/or paraaortic radiotherapy ≤ 28 day prior enrollment study poorly control diabetes mellitus ( HbA1c &gt; 8 % ) history cardiac dysfunction active cardiac disease specify protocol impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BKM120 Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Advanced endometrial cancer</keyword>
	<keyword>PI3K pathway</keyword>
	<keyword>second-line treatment</keyword>
</DOC>